Payment overview · 2025
General Payments
$704.66
38 reported records · 22 companies
Healthcare provider profile · identity verified
John Blumer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BRUNSWICK, GA · NPI 1619984150
Verified facts
What the public records show
CMS Open Payments records show John Blumer, M.D. received $704.66 in general payments during 2025 across 38 reported records.
Abbott Laboratories accounted for 10.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.20 | 10.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.75 | 8.5% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $52.23 | 7.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.35 | 7.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.74 | 6.8% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $44.89 | 6.4% | 2 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $36.07 | 5.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.66 | 5.1% | 2 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $34.72 | 4.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.85 | 4.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.96 | 4.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.60 | 3.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $22.41 | 3.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.33 | 3.2% | 1 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $22.32 | 3.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.62 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.35 | 2.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.36 | 2.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.95 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.51 | 2.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.30 | 2.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $13.49 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $704.66 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $71.20 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.75 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $52.23 | 3 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $44.89 | 2 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $36.07 | 2 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $36.07 | 2 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $36.07 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.66 | 2 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $34.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $31.96 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 117 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 169 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
181 | 35 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
131 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
117 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
169 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
161 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 811 | 178 |
| Gabapentin | Gabapentin | 680 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 669 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 612 | 158 |
| Tramadol Hcl | Tramadol Hcl | 487 | 85 |
| Losartan Potassium | Losartan Potassium | 431 | 115 |
| Omeprazole | Omeprazole | 421 | 107 |
| Trazodone Hcl | Trazodone Hcl | 407 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 374 | 91 |
| Metformin Hcl | Metformin Hcl | 323 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 311 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 282 | 77 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 266 | 73 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 265 | 69 |
| Furosemide | Furosemide | 249 | 77 |
| Metformin Hcl Er | Metformin Hcl | 237 | 55 |
| Methocarbamol | Methocarbamol | 230 | 63 |
| Famotidine | Famotidine | 217 | 51 |
| Lisinopril | Lisinopril | 217 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 55 |
| Januvia | Sitagliptin Phosphate | 194 | 32 |
| Meloxicam | Meloxicam | 186 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 39 |
| Linzess | Linaclotide | 181 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 176 | 43 |
| Azithromycin | Azithromycin | 175 | 127 |
| Fluticasone Propionate | Fluticasone Propionate | 173 | 55 |
| Ozempic | Semaglutide | 169 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 32 |
| Potassium Chloride | Potassium Chloride | 164 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 42 |
| Eliquis | Apixaban | 161 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 159 | 41 |
| Clonazepam | Clonazepam | 155 | 25 |
| Glimepiride | Glimepiride | 155 | 42 |
| Telmisartan | Telmisartan | 150 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 148 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 147 | 34 |
| Montelukast Sodium | Montelukast Sodium | 143 | 29 |
| Mirtazapine | Mirtazapine | 141 | 31 |
| Simvastatin | Simvastatin | 139 | 35 |
| Carvedilol | Carvedilol | 135 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 21 |
| Allopurinol | Allopurinol | 131 | 34 |
| Farxiga | Dapagliflozin Propanediol | 131 | 19 |
| Nifedipine Er | Nifedipine | 131 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 28 |
| Mounjaro | Tirzepatide | 117 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 109 | 37 |
| Bupropion Xl | Bupropion Hcl | 100 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 28 |
| Baclofen | Baclofen | 97 | 24 |
| Chlorthalidone | Chlorthalidone | 88 | 21 |
| Ibuprofen | Ibuprofen | 88 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 87 | 21 |
| Pregabalin | Pregabalin | 87 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 84 | 23 |
| Valacyclovir | Valacyclovir Hcl | 84 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 79 | 17 |
| Glipizide Er | Glipizide | 75 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 17 |
| Sertraline Hcl | Sertraline Hcl | 71 | 19 |
| Azelastine Hcl | Azelastine Hcl | 70 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 17 |
| Estradiol | Estradiol | 66 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 16 |
| Alendronate Sodium | Alendronate Sodium | 61 | 15 |
| Fluconazole | Fluconazole | 61 | 26 |
| Jardiance | Empagliflozin | 61 | 14 |
| Alprazolam | Alprazolam | 60 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 58 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | suppressed |
| Torsemide | Torsemide | 57 | 16 |
| Celecoxib | Celecoxib | 56 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 14 |
| Synthroid | Levothyroxine Sodium | 54 | 12 |
| Methylprednisolone | Methylprednisolone | 52 | 40 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Diazepam | Diazepam | 49 | 12 |
| Lorazepam | Lorazepam | 49 | suppressed |
| Ezetimibe | Ezetimibe | 48 | 16 |
| Prednisone | Prednisone | 48 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Amoxicillin | Amoxicillin | 44 | 31 |
| Lovastatin | Lovastatin | 44 | 11 |
| Mupirocin | Mupirocin | 43 | 23 |
| Spironolactone | Spironolactone | 43 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 31 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 25 |
| Rybelsus | Semaglutide | 34 | suppressed |
| Valsartan | Valsartan | 34 | 11 |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 12 |
| Temazepam | Temazepam | 32 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 28 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 11 |
| Risperidone | Risperidone | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 12 |
| Glipizide | Glipizide | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Sulindac | Sulindac | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nystatin | Nystatin | 15 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 13 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Androgel | Testosterone | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $704.66 · 38 records | Abbott Laboratories | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, Evoke, FREESTYLE LIBRE, General - Pain Management, Grastek, IBSRELA, INSPIRE, JARDIANCE, KRYSTEXXA, Kerendia, MOUNJARO, NURTEC ODT, Odactra, Omnipod, Ozempic, PREVNAR 20, Prospera, QULIPTA, Ragwitek, Rybelsus, SHINGRIX, TZIELD, UBRELVY, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error